BioSpace News Archive

Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today top-line results from a Phase 1 clinical trial evaluating XCUR17 in patients with mild-to-moderate chronic plaque psoriasis. XCUR17 is an SNA drug targeted to mRNA encoding interleukin 17 receptor alpha, or IL-17RA. IL-17RA is a key protein that propagates inflammation.

The approval of this submission triggers a milestone of US$0.5 million for Crescita.

Dr. Rudolph Tanzi is a neuroscientist and geneticist with scientific expertise in Alzheimer’s disease and brain health.

The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields.

10 programs selected to help support healthcare capacity building in resource-constrained countries

lululab, a member company of the K-ICT Born2Global Centre, wins the CES Innovation Awards in the biotech sector ahead of CES 2019, the world’s largest consumer electronics show, to be held in Las Vegas next January.

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection

Precision Medicine Group, Inc. (Precision) today announced it has acquired Stern Investor Relations, Inc. (Stern IR), a leading investor relations firm for entrepreneurial biotechnology and healthcare companies.

March of Dimes, the leading nonprofit organization for maternal and infant health, announced today the opening of its new headquarters in Arlington, Virginia, a suburb of Washington, DC.

Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.